Targeting EZH2 for the treatment of hepatosplenic T-cell lymphoma

Blood Adv. 2020 Apr 14;4(7):1265-1269. doi: 10.1182/bloodadvances.2019001256.

Authors

Yana Pikman^{1

2}, Amy Saur Conway¹, Amanda L Robichaud¹, Samuel Kitara¹, Alanna J Church³, Alyssa L Kennedy^{1

2}, Lewis B Silverman^{1

2}, Amy L Billett^{1

2}, David M Weinstock⁴, Marian H Harris³, Kimberly Stegmaier^{1

2

5}

Affiliations

¹ Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA.
² Division of Hematology/Oncology and.
³ Department of Pathology, Boston Children's Hospital, Boston, MA.
⁴ Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; and.
⁵ Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, MA.

Abstract

We report a patient with hepatosplenic T-cell lymphoma (HSTL) and compare the disease to the derived xenograft model.
Enhancer of zeste homolog 2 (EZH2) inhibitor treatment of an EZH2-mutant HSTL patient-derived xenograft model led to prolonged survival.

Publication types

Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

Humans
Lymphoma, T-Cell* / drug therapy
Receptors, Antigen, T-Cell, gamma-delta

Substances

Receptors, Antigen, T-Cell, gamma-delta

Grants and funding